C型肝炎ウイルス感染：グローバル治療薬の市場予測と分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables15
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 28
3.1.3 Prognosis 29
3.2 Symptoms 29
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 31
4.1.1 The risk of contracting HCV is almost 50 times higher among injection drug users 32
4.1.2 There is a 10.9-fold increased risk of developing HCV infection through a blood transfusion 33
4.1.3 No current preventative therapy to reduce perinatal HCV transmission 33
4.1.4 Metabolic syndrome is a common comorbidity in HCV-infected individuals 34
4.1.5 Chronic alcoholism greatly magnifies the risk of HCC 35
4.1.6 HBV and HCV share similar modes of transmission, resulting in co-infection 35
4.1.7 HCV/HIV co-infection complicates treatment options and accelerates liver damage 35
4.2 Global Trends 36
4.2.1 US 37
4.2.2 5EU 38
4.2.3 Japan 41
4.2.4 Brazil 41
4.2.5 China 42
4.3 Forecast Methodology 43
4.3.1 Sources Used 43
4.3.2 Forecast Assumptions and Methods 47
4.3.3 Forecast Assumptions and Methods (HCV Genotypes) 51
4.3.4 Sources Not Used 55
4.4 Epidemiology Forecast for HCV (2012-2022) 55
4.4.1 Total Prevalent Cases of HCV 55
4.4.2 Age-Specific Prevalent Cases of HCV 58
4.4.3 Sex-Specific Prevalent Cases of HCV 61
4.4.4 Age-Standardized Prevalence of HCV 64
4.4.5 HCV Genotype Class Distributions 66
4.5 Discussion 67
4.5.1 Conclusion on Epidemiology Trends 67
4.5.2 Limitations of the Analysis 68
4.5.3 Strengths of the Analysis 69
5 Disease Management 70
5.1 Diagnosis and Referral Overview 70
5.2 Treatment Overview 71
5.3 US 74
5.3.1 Diagnosis 74
5.3.2 Clinical Practice 76
5.4 France 79
5.4.1 Diagnosis 79
5.4.2 Clinical Practice 80
5.5 Germany 81
5.5.1 Diagnosis 81
5.5.2 Clinical Practice 82
5.6 Italy 83
5.6.1 Diagnosis 83
5.6.2 Clinical Practice 83
5.7 Spain 84
5.7.1 Diagnosis 84
5.7.2 Clinical Practice 84
5.8 UK 86
5.8.1 Diagnosis 86
5.8.2 Clinical Practice 87
5.9 Japan 88
5.9.1 Diagnosis 88
5.9.2 Clinical Practice 88
5.10 Brazil 89
5.10.1 Diagnosis 89
5.10.2 Clinical Practice 90
5.11 China 90
5.11.1 Diagnosis 90
5.11.2 Clinical Practice 91
6 Competitive Assessment 92
6.1 Overview 92
6.2 Strategic Competitor Assessment 92
6.3 Product Profiles – Major Brands 94
6.3.1 Sovaldi and Sovaldi/Ledipasvir 94
6.3.2 Olysio 106
6.3.3 Incivek 114
6.3.4 Victrelis 121
6.3.5 Pegasys 127
6.3.6 PegIntron 133
6.3.7 Copegus, Rebetol, and Generic Ribavirin 139
6.3.8 Therapeutic Class: Interferon 144
7 Opportunity and Unmet Need 145
7.1 Overview 145
7.2 Unmet Needs 146
7.2.1 Unmet Need: Enhanced Efficacy in Difficult-to-Treat Patient Populations 146
7.2.2 Unmet Need: Improved Understanding of Drug-Drug Interactions 147
7.2.3 Unmet Need: Increased Disease Awareness and Diagnosis of HCV 148
7.2.4 Unmet Need: Reduced Cost of All-Oral Regimens 149
7.2.5 Unmet Need: Improved Treatment Tolerability 149
7.2.6 Unmet Need: Simplified Treatment Algorithm 150
7.2.7 Unmet Need: Shorter Treatment Duration 151
7.3 Unmet Needs Gap Analysis 152
7.4 Opportunities 153
7.4.1 Opportunity: Develop a Pan-Genotypic, All-Oral HCV Regimen 153
7.4.2 Opportunity: Target Difficult-to-Treat Patient Populations 153
7.4.3 Opportunity: Eliminate Ribavirin from All-Oral Regimens 154
7.4.4 Opportunity: Involvement of the Immune System 155
8 Pipeline Assessment 156
8.1 Overview 156
8.2 Clinical Trial Mapping 157
8.2.1 Clinical Trials by Country 157
8.3 Clinical Trials by Phase and Trial Status 158
8.4 Promising Direct-Acting Antivirals (DAAs) in Clinical Development 160
8.4.1 ABT-450/Ombitasvir + Dasabuvir 162
8.4.2 Faldaprevir 172
8.4.3 Daclatasvir, Daclatasvir + Asunaprevir, and Daclatasvir/Asunaprevir/BMS-791325 181
8.4.4 MK-5172/MK-8742 194
8.4.5 Vaniprevir 202
8.5 Other Drug Classes in Clinical Development 208
8.5.1 Interferon Derivatives 208
8.5.2 Host-Targeting Therapies 210
9 Current and Future Players 212
9.1 Overview 212
9.2 Trends in Corporate Strategy 214
9.3 Company Profiles 216
9.3.1 Merck 216
9.3.2 Roche 218
9.3.3 Vertex 221
9.3.4 Janssen 224
9.3.5 Gilead 226
9.3.6 AbbVie 231
9.3.7 Bristol-Myers Squibb 233
9.3.8 Boehringer Ingelheim 236
9.4 Additional Companies with Promising Drugs 239
9.4.1 Mitsubishi Tanabe Pharmaceutical Corporation 239
9.4.2 Achillion 240
9.4.3 Scynexis 241
9.4.4 Idenix 242
9.4.5 Presidio 243
9.4.6 Novartis 244
10 Market Outlook 246
10.1 Global Markets 246
10.1.1 Forecast 246
10.1.2 Drivers and Barriers – Global Issues 250
10.2 US 255
10.2.1 Forecast 255
10.2.2 Key Events 261
10.2.3 Drivers and Barriers 262
10.3 France 266
10.3.1 Forecast 266
10.3.2 Key Events 272
10.3.3 Drivers and Barriers 273
10.4 Germany 275
10.4.1 Forecast 275
10.4.2 Key Events 280
10.4.3 Drivers and Barriers 281
10.5 Italy 283
10.5.1 Forecast 283
10.5.2 Key Events 287
10.5.3 Drivers and Barriers 288
10.6 Spain 290
10.6.1 Forecast 290
10.6.2 Key Events 294
10.6.3 Drivers and Barriers 295
10.7 UK 297
10.7.1 Forecast 297
10.7.2 Key Events 302
10.7.3 Drivers and Barriers 303
10.8 Japan 305
10.8.1 Forecast 305
10.8.2 Key Events 311
10.8.3 Drivers and Barriers 312
10.9 Brazil 314
10.9.1 Forecast 314
10.9.2 Key Events 318
10.9.3 Drivers and Barriers 318
10.10 China 321
10.10.1 Forecast 321
10.10.2 Key Events 325
10.10.3 Drivers and Barriers 325
11 Appendix 328
11.1 Bibliography 328
11.2 Abbreviations 358
11.3 Methodology 361
11.4 Forecasting Methodology 361
11.4.1 Percent Drug-Treated Patients 361
11.4.2 Patient Warehousing 362
11.4.3 Drugs Included in Each Therapeutic Class 362
11.4.4 Launch and Patent Expiry Dates 363
11.4.5 General Pricing Assumptions 364
11.4.6 Individual Drug Assumptions 365
11.4.7 Generic Erosion 369
11.4.8 Selection of Pipeline Agents 369
11.4.9 Pricing of Pipeline Agents 370
11.5 Physicians and Specialists Included in This Study 374
11.6 Survey of Prescribing Physicians 376
11.7 About the Authors 377
11.7.1 Analysts 377
11.7.2 Epidemiologist 378
11.7.3 Therapy Area Director 378
11.7.4 Global Head of Healthcare 379
11.8 About GlobalData 380
11.9 Disclaimer 380